Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCrimson Tide Regulatory News (TIDE)

Share Price Information for Crimson Tide (TIDE)

Share Price is delayed by 15 minutes
Get Live Data
90.00    0.00 (0.00%)
Bid:
85.00
Ask:
95.00
Spread: 10.00 (11.765%)
Market Cap: £5.92m
TIDE Live PriceLast checked at - London Stock Exchange

Intraday Crimson Tide Share Chart

Long Term Contract with NCHCD

12 Oct 2016 07:00

RNS Number : 2818M
Crimson Tide PLC
12 October 2016
 

Crimson Tide PLC

("Crimson Tide" or the 'Company')

Crimson Tide signs long term contract with National Centre for Hereditary Coagulation Disorders (NCHCD)

 

Crimson Tide ﴾TIDE﴿, the AIM‐quoted provider of mpro5 ‐ Smart Mobility as a Service, has entered into a contract with the NCHCD in Ireland, whereby mpro5 will deliver its healthcare solution to patients in the management of treatment for hereditary coagulation disorders, commonly known as haemophilia.

 

The contract value is worth approximately €140,000 in revenue over a term of 36 months, which includes delivery of the mpro5 mobility solution directly to patients. This is the first contract Crimson Tide has signed directly with the NCHCD as previously its solutions were delivered via a third party.

 

Patients at home use mpro5 to scan medication they receive from the hospital. The barcode information is then sent to a central hub for verification of type and date ranges. Confirmation is then returned to the patient, informing them of the medication validity and safe administration.

 

New functionality now improves this process, - including verification of stock levels and expiry date prompts, thereby providing further information to the patient and assisting in reducing stock wastage.

 

Barrie Whipp, Executive Chairman of Crimson Tide, said: "We are delighted to be able to work directly with the NCHCD in providing patients with hereditary coagulation disorders a solution to manage their use of prescribed pharmaceutical products. This empowers patients to manage their condition and provides the NCHCD with valuable real time information."

 

For further information:

Crimson Tide plc

 

Barrie Whipp/Steve Goodwin 01892 542 444

 

WH Ireland

James Joyce /James Bavister 020 7220 1666

 

Notes to editors

1. Founded in 1996 and quoted on AIM since 2006, Crimson Tide plc is the provider of mpro5 ‐ Smart Mobility as a Service (SMaaS). mpro5 is delivered on smartphones, tablets and PDAs, and enables companies to transform their businesses and strengthen their workforces.

2. Crimson Tide offers a global service, working with some of the world's leading companies, tailoring mpro5 to suit customer needs. Developed over 10 years by its world‐class team, mpro5 is the smart choice for organisations large and small that want to improve productivity and save money.

3. mpro5 is a platform‐agnostic mobility suite fully hosted on Microsoft Azure, so customers are quickly up and running and the service is scalable and robust. It is provided on subscription, so clients can immediately see a return on their investment.

4. mpro5 not only helps people improve their day‐to‐day working methods while saving employers money, it also saves lives, by enabling haemophilia patients to verify the safety of their medication before use. mpro5 clients come from a diverse range of industries allowing the Company to listen, share and find the best solution for all mobility needs.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAKFLFFQBFEFBD
Date   Source Headline
14th Dec 20167:00 amRNSTrading Update and Contract Rollout
18th Nov 20169:45 amRNSDirector/PDMR Shareholding
13th Oct 20167:00 amRNSSignificant long term contract win
12th Oct 20167:00 amRNSLong Term Contract with NCHCD
22nd Sep 20167:00 amRNSInterim Results
18th Jul 20167:00 amRNSCrimson Tide selected by large UK retailer
14th Jul 20167:00 amRNSPharmaceutical Verification Pilot
29th Jun 20168:31 amRNSResult of AGM
14th Jun 20167:00 amRNSMpro5 Contract Win
3rd Jun 20163:47 pmRNSFinal Results and Notice of AGM
20th May 20163:26 pmRNSExercise of Options
20th Apr 20167:00 amRNSPreliminary Results
25th Feb 20167:00 amRNSTrading Update
24th Feb 20163:34 pmRNSResult of Court Hearing
26th Jan 20162:37 pmRNSResult of General Meeting
30th Dec 20157:00 amRNSProposed Reconstruction of Capital
4th Dec 20157:00 amRNSUpdate on Significant Contract Win
7th Oct 20155:58 pmRNSHolding(s) in Company
1st Oct 20152:45 pmRNSDirector's Dealing
30th Sep 20157:00 amRNSInterim Results
17th Sep 20157:00 amRNSSignificant contract win
1st Jul 20157:00 amRNSResult of AGM
8th Jun 20157:00 amRNSFinal Results and Notice of AGM
4th Jun 20157:00 amRNSSignificant Contract Win
14th Apr 20157:00 amRNSContracts Update
2nd Apr 20157:00 amRNSPreliminary Results
20th Mar 201510:03 amRNSDirectorate Change
3rd Mar 20157:00 amRNSTrading Update
24th Feb 20157:00 amRNSNew Finance Facilities
30th Jan 20155:02 pmRNSHolding(s) in Company
11th Dec 20147:00 amRNSAppointment of Director
29th Oct 20147:00 amRNSContract win for mpro5
14th Oct 20147:00 amRNSContract win for mpro
23rd Sep 20147:00 amRNSInterim Results
1st Sep 20147:00 amRNSSignificant contract win takes Crimson Tide Global
23rd Jul 20142:28 pmRNSHolding(s) in Company
5th Jun 20144:30 pmRNSDirector's Dealing
4th Jun 20147:00 amRNSContract Extensions for MPRO5 worth over £200k
30th May 20145:35 pmRNSFinal Results and Notice of AGM
10th Apr 20148:56 amRNSHolding(s) in Company
2nd Apr 20147:00 amRNSPreliminary Results
10th Mar 20147:00 amRNSStrategic Partnership Agreement
30th Oct 201311:22 amRNSTR-1: Notification of major interest in shares
29th Oct 20137:00 amRNSContract Extension
20th Sep 20137:05 amRNSNew Contract Wins
20th Sep 20137:00 amRNSInterim Results
17th Sep 20137:00 amRNSContract Extension
23rd Aug 20132:20 pmRNSChange of responsibilities
28th Jun 20133:23 pmRNSResult of AGM
6th Jun 20137:00 amRNSFinal Accounts and AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.